Evidence map›Paper›PMID 31330838›Full record

ReviewInternational journal of molecular sciences2019

Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia.

Mohammad Amin Moosavi, Mojgan Djavaheri-Mergny

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. STIM1 in tumor cell death: angel or devil?Cell death discovery · 2023
    Review
  14. Review
  15. Review
  16. Mechanistic update of Trisenox in blood cancer.Current research in pharmacology and drug discovery · 2023
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Mohammad Amin MoosaviDepartment of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology, Tehran 14965/161, Iran.ORCID 0000-0001-9958-2220
Mojgan Djavaheri-MergnyEquipe labellisée par la Ligue contre le cancer, Université Paris Descartes, Université Sorbonne Paris Cité, Université Paris Diderot, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris 75006, France. mojgan.mergny@inserm.fr.ORCID 0000-0003-4893-6505
Inserm · FRNational Institute of Genetic Engineering and Biotechnology · IR

Funding

Institut National de la Santé et de la Recherche Médicale 1Ligue Contre le Cancer 1National Institute of Genetic Engineering and Biotechnology 1
6 · The paper itself

Abstract

Autophagy is one of the main cellular catabolic pathways controlling a variety of physiological processes, including those involved in self-renewal, differentiation and death. While acute promyelocytic leukemia (APL) cells manifest low levels of expression of autophagy genes associated with reduced autophagy activity, the introduction of all-

Indexed as

Arsenic TrioxideAutophagyCell DifferentiationDrug Resistance, NeoplasmHumansLeukemia, Promyelocytic, AcuteArsenic TrioxideAcute promyelocytic leukemiaall-trans retinoid acidarsenic trioxideautophagycell survivaldifferentiationresistance to therapy

Identifiers

PMID31330838
PMCPMC6678259
OpenAlexW2962844727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.